{"id":"NCT01856309","sponsor":"Janssen Research & Development, LLC","briefTitle":"Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003","officialTitle":"A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (Sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO136ARA3003 (SIRROUND-T)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-08-07","primaryCompletion":"2018-04-30","completion":"2018-04-30","firstPosted":"2013-05-17","resultsPosted":"2019-05-06","lastUpdate":"2019-05-06"},"enrollment":1820,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Rheumatoid"],"interventions":[{"type":"DRUG","name":"Sirukumab 100 mg","otherNames":[]},{"type":"DRUG","name":"Sirukumab 50 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sirukumab 100 mg","type":"EXPERIMENTAL"},{"label":"Sirukumab 50 mg / placebo","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the long-term safety and efficacy of CNTO 136 (sirukumab) in participants with rheumatoid arthritis (RA) who are unresponsive to treatment with modifying antirheumatic drugs (DMARDs) or anti-TNF alpha agents.","primaryOutcome":{"measure":"Percentage of Participants With Serious Adverse Events (SAEs)","timeFrame":"From baseline of this LTE study up to 4.3 years","effectByArm":[{"arm":"Placebo to 50 mg q4w Due to EE/LE/CO","deltaMin":21.3,"sd":null},{"arm":"Placebo to 100 mg q2w Due to EE/LE/CO","deltaMin":27.8,"sd":null},{"arm":"Sirukumab 50 mg q4w","deltaMin":26.4,"sd":null},{"arm":"Sirukumab 100 mg q2w","deltaMin":23.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":197,"countries":["United States","Argentina","Australia","Austria","Belgium","Bulgaria","Canada","Chile","Colombia","Croatia","France","Germany","Japan","Lithuania","Malaysia","Mexico","Netherlands","Poland","Portugal","Puerto Rico","Romania","Russia","Serbia","South Africa","South Korea","Spain","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":["33526709"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":65,"n":305},"commonTop":["Viral upper respiratory tract infection","Rheumatoid arthritis","Upper respiratory tract infection","Alanine aminotransferase increased","Bronchitis"]}}